Selective and potent dopamine D2/D3 receptor antagonist (Ki values are 1.8, 3.5, 2400 and 18000 nM for D2, D3, D4 and D1 receptors respectively). Centrally active following systemic administration in vivo.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 347.24. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.88 mL||14.4 mL||28.8 mL|
|5 mM||0.58 mL||2.88 mL||5.76 mL|
|10 mM||0.29 mL||1.44 mL||2.88 mL|
|50 mM||0.06 mL||0.29 mL||0.58 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Hall et al (1989) Animal pharmacology of raclopride, a selective dopamine D2 antagonist. Psychopharmacol.Ser. 7 123 PMID: 2687851
Ogren et al (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90 287 PMID: 2947255
Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264 PMID: 7940991
If you know of a relevant reference for Raclopride, please let us know.
View Related Products by Product Action
Keywords: Potent selective D2/D3 antagonists Dopamine D2-like Non-Selective Receptors dopaminergic Non-selective Dopamine
8 Citations for Raclopride
Citations are publications that use Tocris products. Selected citations for Raclopride include:
Scardochio et al (2015) The Effects of Electrical and Optical Stimulation of Midbrain Dopaminergic Neurons on Rat 50-kHz Ultrasonic Vocalizations. Front Behav Neurosci 9 331 PMID: 26696851
Jiang et al (2015) SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway. Psychopharmacology (Berl) 18 PMID: 25522427
Heath et al (2015) Motivational assessment of mice using the touchscreen operant testing system: effects of dopaminergic drugs. Psychopharmacology (Berl) 232 4043 PMID: 26156636
Chiodi et al (2014) Cocaine-induced changes of synaptic transmission in the striatum are modulated by adenosine A2A receptors and involve the tyrosine phosphatase STEP. Neuropsychopharmacology 39 569 PMID: 23989619
Zheng et al (2014) Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes. J Neurosci 306 R138 PMID: 24305061
Ahmadiantehrani and Ron (2013) Dopamine D2 receptor activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gβγ-Erk1/2-dependent induction of Zif268. J Neurochem PMID: 23373701
Ogata et al (2012) Dopamine and full-field illumination activate D1 and D2-D5-type receptors in adult rat retinal ganglion cells. J Comp Neurol 520 4032 PMID: 22678972
Liu et al (2008) Increased dopamine level enhances male-male courtship in Drosophila. Int J Neuropsychopharmacol 28 5539 PMID: 18495888
Do you know of a great paper that uses Raclopride from Tocris? If so please let us know.
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.